Sibling stem cell transplant with special immune cells for high-risk leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether a stem cell transplant from your matched sibling, combined with specially selected immune cells, can help treat aggressive forms of acute myeloid leukemia (AML, a blood cancer). The goal is to improve outcomes for patients whose leukemia is at high risk of returning.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have acute myeloid leukemia (AML) that is either in remission or nearly in remission, with certain high-risk genetic changes
- You have a brother or sister who is a perfect genetic match (HLA-matched) and can donate stem cells
- You are between 18 and 70 years old and healthy enough to tolerate intensive chemotherapy before the transplant
- Your heart, lungs, liver, and kidneys are working well enough for this procedure
- You have not had a stem cell transplant before
- You agree to participate and sign the informed consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a type of stem cell transplant (using cells from a partially matched donor and umbilical cord blood) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The goal is to help patients whose disease is high-risk, has returned after treatment, or hasn't responded well to chemotherapy.
This trial tests a special transplant approach for people with high-risk acute leukemia. It uses a stronger dose of radiation before transplant, followed by an infusion of immune cells (regulatory and conventional T cells) to help the transplant work better and fight the leukemia.
This trial tests a stem cell transplant from a partially matched family member combined with donor immune cells and targeted drugs for acute myeloid leukemia (AML) that hasn't responded to standard treatment. The goal is to help patients who have few other options.
This Phase 1 trial tests a special bone marrow transplant using a related “half-matched” donor (haploidentical), without a specific immune-suppressing medicine (“IS-free”). It’s for adults with certain high-risk AML or MDS to see if this approach can improve control of the disease while tracking safety.
This trial tests a gentler chemotherapy regimen before a stem cell transplant from a partially matched family donor for patients with acute myeloid leukemia (AML) who are older or have health conditions that make standard transplants risky. The goal is to help patients achieve long-term remission with fewer serious side effects.
This trial tests a specialized donor stem cell transplant to treat high-risk problems in the blood and bone marrow, including some cancers and non-cancers. It may help by using donor immune cells designed to better control the disease after transplant.
Hear when a new AML (Acute Myeloid Leukemia) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.